These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 22500986)

  • 21. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
    Shapiro CL; Moriarty JP; Dusetzina S; Himelstein AL; Foster JC; Grubbs SS; Novotny PJ; Borah BJ
    J Clin Oncol; 2017 Dec; 35(35):3949-3955. PubMed ID: 29023215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
    Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
    Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic review of the role of bisphosphonates in metastatic disease.
    Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
    Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
    Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
    Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reducing the burden of bone metastases: current concepts and treatment options.
    von Moos R; Sternberg C; Body JJ; Bokemeyer C
    Support Care Cancer; 2013 Jun; 21(6):1773-83. PubMed ID: 23468364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
    Wellington K; Goa KL
    Drugs; 2003; 63(4):417-37. PubMed ID: 12558465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
    Saba N; Khuri F
    Oncology; 2005; 68(1):18-22. PubMed ID: 15775689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
    Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
    J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
    Xie F; Hopkins RB; Burke N; Habib M; Angelis CD; Pasetka M; Giotis A; Goeree R
    Hosp Pract (1995); 2014 Apr; 42(2):38-45. PubMed ID: 24769783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.
    Terpos E; Jamotte A; Christodoulopoulou A; Campioni M; Bhowmik D; Kennedy L; Willenbacher W
    J Med Econ; 2019 Aug; 22(8):766-776. PubMed ID: 30969797
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases.
    Koo K; Lam K; Mittmann N; Konski A; Dennis K; Zeng L; Lam H; Chow E
    Support Care Cancer; 2013 Jun; 21(6):1785-91. PubMed ID: 23519570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Brufsky A; Kennedy L; Bhatta S; Bhowmik D; Buchanan J; Despiegel N; Hechmati G
    J Med Econ; 2020 Jan; 23(1):37-47. PubMed ID: 31364885
    [No Abstract]   [Full Text] [Related]  

  • 37. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
    Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
    Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
    Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
    J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
    Smith MR; Halabi S; Ryan CJ; Hussain A; Vogelzang N; Stadler W; Hauke RJ; Monk JP; Saylor P; Bhoopalam N; Saad F; Sanford B; Kelly WK; Morris M; Small EJ
    J Clin Oncol; 2014 Apr; 32(11):1143-50. PubMed ID: 24590644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.
    Stoffel ST; von Moos R; Thürlimann B; Cathomas R; Gillessen S; Zürrer-Härdi U; von Briel T; Anchisi S; Feller A; Schär C; Dietrich D; Schwenkglenks M; Lupatsch JE; Mark MT
    Swiss Med Wkly; 2021 Mar; 151():w20464. PubMed ID: 33705559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.